RxDoctor Payments Data

Sasrutha Wickramasinghe

Cardiovascular Disease · Houston, TXNPI 1326209404

Payments from drug & device makers

$34,939in general payments, 2019–2025

Across 382 payments — averaging $91.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$11K
  • Biotronik Inc.$10K
  • Abbott$4K
  • Boston Scientific$3K
  • Merck$631
  • Amgen$494
  • plus $5K from 36 others

What the payments were for

  • Speaking & faculty fees$9,75028%
  • Travel & lodging$14,70442%
  • Food & beverage$10,47130%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,939 in reported general payments places this provider in the 80th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$563,046
Medicare patients
1,272
Services billed
5,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban570$609,537
XareltoRivaroxaban204$239,626
EntrestoSacubitril/Valsartan132$161,336
JardianceEmpagliflozin92$114,364
BrilintaTicagrelor68$58,791
Repatha SureclickEvolocumab19$16,591
FarxigaDapagliflozin Propanediol14$15,615
VerquvoVericiguat12$10,270
Metoprolol Succinate431$6,505
Atorvastatin Calcium564$5,547
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide121$4,138
Amiodarone Hcl63$4,044
Carvedilol362$3,885
ClopidogrelClopidogrel Bisulfate301$3,689
Dabigatran EtexilateDabigatran Etexilate Mesylate18$3,581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$173$609,537570 claims
Johnson & JohnsonXarelto$117$239,626204 claims
NovartisEntresto$463$161,336132 claims
Boehringer IngelheimJardiance$246$114,36492 claims
AstraZenecaBrilinta, Farxiga$330$74,40682 claims
MerckVerquvo$631$10,27012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →